Conkwest, which is developing cancer immunotherapies based on natural killer cells, filed on Friday with the SEC to raise up to $173 million in an initial public offering.
The Cardiff-by-the-Sea, CA-based company, which was founded in 2002, plans to list on the NASDAQ under the symbol CONK.RC. Conkwest initially filed confidentially on May 14, 2015. BofA Merrill Lynch, Citi, Jefferies and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
